IP Library › Granted Patent US 12,565,539
Granted Patent B2
US 12,565,539 · App. 18/516,127 · Granted Mar 3, 2026

Method for primary prevention of allergic disorders during infancy through IgE-class-specific immunosuppression

Inventors: Hirohisa Saito (Saitama, JP); Kenji Matsumoto (Tokyo, JP); Hideaki Morita (Tokyo, JP); Go Ichien (Tokyo, JP); Yasuhiko Koezuka (Tokyo, JP); Kimishige Ishizaka (Carlisle, MA)
Assignees: HUBIT GENOMIX, INC.; NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT; Yutaka Ishizaka
C07K16/4291A61P37/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,565,539
App. No.
18/516,127
Granted
Mar 3, 2026
Kind
B2
Abstract

The disclosure provides a pharmaceutical composition containing an anti-IgE antibody that suppresses the production of allergen-specific IgE antibodies and methods of use thereof.

Claims (22)

1 . A method of decreasing a risk of an allergic predisposition in a subject, the method comprising

administering an effective amount of an anti-IgE antibody to the subject, and

administering an effective amount of an allergen to the subject,

wherein the subject is not sensitized to an allergen that causes the allergic predisposition and is in infancy or younger; and

the anti-IgE antibody is administered during a newborn stage, an early infancy, or an infancy, or the anti-IgE antibody is full-length.

2 . A method of suppressing production of allergen-specific IgE antibodies in a subject, comprising administering an effective amount of an anti-IgE antibody to the subject,

wherein the subject is not sensitized to an allergen that causes the allergic predisposition and is in infancy or younger.

3 . The method according to claim 1 , wherein the subject is human.

4 . The method according to claim 1 , wherein the method comprises administering the effective amount of the anti-IgE antibody to a mother pregnant with the subject.

5 . The method according to claim 4 , wherein the mother is not diagnosed with asthma.

6 . The method according to claim 4 , wherein the mother is not diagnosed with an allergic disorder.

7 . The method according to claim 1 , wherein the subject is not diagnosed with asthma.

8 . The method according to claim 1 , wherein the subject is not diagnosed with an allergic disorder.

9 . The method according to claim 1 , wherein the method comprises administering the effective amount of the anti-IgE antibody to the subject during the newborn stage.

10 . The method according to claim 1 , wherein the method comprises administering the effective amount of the anti-IgE antibody to the subject during the early infancy.

11 . The method according to claim 1 , wherein the method comprises administering the effective amount of the anti-IgE antibody to the subject during the infancy.

12 . The method according to claim 1 , wherein the method decreases a probability for an onset of an allergic disorder in the subject during infancy and later.

13 . The method according to claim 1 , wherein the allergen is food allergen.

14 . The method according to claim 1 , wherein the allergen comprises peanut.

15 . The method according to claim 1 , wherein the anti-IgE antibody comprises omalizumab.

16 . The method according to claim 4 , wherein the mother has not taken the anti-IgE antibody previously.

17 . The method according to claim 1 , wherein the anti-IgE antibody is a full-length IgG.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2025
From: ISHIZAKA, KIMISHIGE
To: ISHIZAKA, YUTAKA
Reel/Frame 073299/0395 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2024
From: ICHIEN, GO; KOEZUKA, YASUHIKO
To: HUBIT GENOMIX,INC.
Reel/Frame 066905/0719 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2024
From: SAITO, HIROHISA; MATSUMOTO, KENJI; MORITA, HIDEAKI
To: NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT
Reel/Frame 066905/0972 →
Priority Claims (1)
JP 2017-214455 · Nov 7, 2017 · national
Continuity (3)
Continuation 16841527 · Apr 6, 2020
Continuation PCTJP2018039614 · Oct 25, 2018
Related Publication 20250163185A1 · May 22, 2025
References Cited (34)
US 7871624B2 · Grubb · 2011 [cited by examiner]
US 8071097B2 · Wu · 2011 [cited by examiner]
US 8137670B2 · Wu · 2012 [cited by examiner]
US 10047166B2 · Chen · 2018 [cited by examiner]
US 11827719B2 · Saito · 2023 [cited by examiner]
US 20020006402A1 · Anderson · 2002 [cited by examiner]
EA 011302B1 · 2009 [cited by applicant]
EA 018068B1 · 2013 [cited by applicant]
JP H06500780A · 1994 [cited by applicant]
WO 0204053A1 · 1992 [cited by applicant]
WO 0151076A1 · 2001 [cited by applicant]
WO WO03057249A1 · 2003 [cited by examiner]
WO WO2005078442A1 · 2005 [cited by examiner]
WO WO2019093137A1 · 2019 [cited by examiner]
Janeway et al., Immunobiology, 3rd edition, Garland Publishing Inc., 1997, pp. 8:18-8:19. [cited by examiner]
Vaughn et al., Structure. Jan. 15, 1998;6(1):63-73. doi: 10.1016/s0969-2126(98)00008-2. PMID: 9493268. [cited by examiner]
Pyzik et al., J Immunol. May 15, 2015;194(10):4595-603. doi: 10.4049/jimmunol.1403014. PMID: 25934922 PMCID: PMC4451002. [cited by examiner]
International Search Report issued in related International Patent Application No. PCT/JP2018/039614 dated Dec. 18, 2018. [cited by applicant]
Dufour et al., “Successful management of severe infant bullous pemphigoid with malizumab,” British Journal of Dermatology, 166 (5): 1140-1142 (2012). [cited by applicant]
Nigro et al., “Passive Immunization during Pregnancy for Congenital Cytomegalovirus Infection,” The New England Journal of Medicine, 353 (13): 1350-1362 (2005). [cited by applicant]
Kuehr et al., “Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis,” Journal of Allergy Clinical Immunology, 109 (2): 27… [cited by applicant]
Partial Supplementary European Search Report issued in corresponding European Patent Application No. 18875171.3 dated Jul. 30, 2021. [cited by applicant]
Pawankar et al., “Overview on the pathomechanisms of allergic rhinitis,” Asia Pacific Allergy, 157-167 (2011). [cited by applicant]
Haba et al., “Inhibition of IgE synthesis by anti-IgE: Role in long-term inhibition of IgE synthesis by neonatally administered soluble IgE,” PNAS, 87: 3363-3367 (1990). [cited by applicant]
Vassella et al., “High anti-IgE levels at birth are associated with a reduced allergy prevalence in infants at risk: a prospective study,” Clinical and Experimental Allergy, 24: 771-777 (1994). [cited by applicant]
Glovsky et al., “Effect of maternal immunotherapy on immediate skin test reactivity, specific rye I IgGE and IgE antibody, and total IgE of the children,” Annals of Allergy, 67: 21-24 (1991). [cited by applicant]
McBain et al., “Anti-D administration in pregnancy for preventing Rhesus alloimmunisation,” The Cochrane Database of Systematic Reviews, 9: CD000020 (2015). [cited by applicant]
Morita et al., “IgE-class-specific immunosuppression in offspring by administration of anti-IgE to pregnant mice,” Journal of Allergy and Clinical Immunology, 143 (3): 1261-1264 (2019). [cited by applicant]
English translation of Office Action issued in corresponding Russian Patent Application No. 2020113059 dated Jun. 15, 2022. [cited by applicant]
English translation of Search Report issued in corresponding Russian Patent Application No. 2020113059 dated Jun. 15, 2022. [cited by applicant]
Janeway CA Jr, Travers P, Walport M. et al. Immunobiology: The Immune System in Health andDisease. 5th edition, New York: Garland Science; 2001 (Year: 2001). [cited by applicant]
Bosquet, J., et al. European Respiratory Review 17,107 (2008): 109 (Year: 2008). [cited by applicant]
Palmeira, Patricia et al. Clinical & developmental immunology vol. 2012 (2012): 985646 (Year: 2012). [cited by applicant]
Normansell, Rebecca, et al., Cochrane database of systematic reviews 1 (2014) (Year: 2014). [cited by applicant]